Mereo BioPharma Group plc (MREO) revenue
Only 2 fiscal years of revenue are on record here for Mereo BioPharma Group plc (MREO); a history needs at least 3. Figures as of 18 Nov 2026, 11:51 UTC, from Yahoo Finance.
Key facts
- Revenue, fiscal 2025
- $500.00K
- Fiscal years on record
- 22023–2025
Figures as of . Statements from Yahoo Finance. Amounts are in USD. Figures, not advice.
Not enough data
A history of revenue needs at least 3 fiscal years; 2 are on record here for Mereo BioPharma Group plc. Nothing is estimated to fill the gap. What is on record is in the table below.
Mereo BioPharma Group plc revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2025 | $500.00K | — | |
| 2023 | $10.00M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Mereo BioPharma Group plc, figure by figure
- Mereo BioPharma Group plc market cap
- Mereo BioPharma Group plc earnings
- Mereo BioPharma Group plc earnings per share (EPS)
- Mereo BioPharma Group plc P/E ratio
- Mereo BioPharma Group plc P/S ratio
- Mereo BioPharma Group plc P/B ratio
- Mereo BioPharma Group plc free cash flow
- Mereo BioPharma Group plc operating margin
- Mereo BioPharma Group plc dividend
- Mereo BioPharma Group plc shares outstanding
- Mereo BioPharma Group plc total debt
- Mereo BioPharma Group plc cash on hand
- Mereo BioPharma Group plc total assets
- Mereo BioPharma Group plc return on equity (ROE)
- Mereo BioPharma Group plc return on invested capital (ROIC)
Mereo BioPharma Group plc (MREO) overview: price, valuation and scorecard
Mereo BioPharma Group plc revenue: questions and answers
How is Mereo BioPharma Group plc's revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Mereo BioPharma Group plc it is on record here for 2 fiscal years, 2023 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Mereo BioPharma Group plc (MREO) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/MREO/revenue
Underlying data: Yahoo Finance.